Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal trial targets had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis indiv